Carina Kern

Dr. Kern is the CEO of LinkGevity, an AI-powered biotech company driving innovation in drug discovery for aging and resilience loss. With a distinguished background in Molecular Biology, Pharmacology, Evolutionary Biology, and Genetics, Carina is known for her pioneering work on aging mechanisms and lifespan extension. Her labs are based at the Babraham Research Campus, affiliated with the University of Cambridge. Her research has led to the development of a first-in-class necrosis inhibitor targeting cellular degeneration (Anti-Necrotic™). This novel therapeutic is ready to begin Phase II clinical trials, as a potential breakthrough treatment for aging. The Anti-Necrotic™ has been backed by numerous strategic UK Government and EU grants, scientific institutions, NHS collaboration and UK Space Agency. It was also selected as one of only 12 global innovations for NASA’s Space-Health program, recognizing its potential to mitigate accelerated aging in astronauts on long-duration space missions.